Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Sigilon Therapeutics’s technology has the ability to completely transform how we treat patients with chronic diseases. Originated from Robert Langer and Daniel Anderson’s laboratories of MIT and was patented and published in three seminal reports in Nature Materials, Nature Biotechnology, and Nature Medicine in 2015 and 2016. The company is based in Cambridge, MA and is funded by Flagship Pioneering. Now is the time to get in on the ground floor of a fast growing company with a very interactive and open culture. Please forward your application via email to email@example.com
Sigilon Therapeutics is searching for an energized candidate to lead a new team focused on CMC and manufacturing a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge pancreatic islet cell technology. This individual would have primary responsibility for all aspects of CMC and manufacturing including: process development, analytical development, CMC, and QA. Initial emphasis will be on partnering with the research team to create a protocol that can be transferred to a CMO. In addition, qualifying, negotiating with and oversight of a CMO is critical. The team will have full access to all of Sigilon’s cell biology and encapsulation chemistry expertise along with substantial designated funds to enable a rapid pursuit of a very robust and competitive program.